Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study. - Wikidata - awgldk - TriplyDB

Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study.

Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study.

http://www.wikidata.org/entity/Q44799322

about

Current stage in inflammatory bowel disease: What is next?Medical Therapy of Active Ulcerative Colitis Profile of lebrikizumab and its potential in the treatment of asthma Novel Therapies for Eosinophilic Disorders Role of type 2 immunity in intestinal inflammation The Link between the Appendix and Ulcerative Colitis: Clinical Relevance and Potential Immunological Mechanisms.First case report of exacerbated ulcerative colitis after anti-interleukin-6R salvage therapy From genetics to treatment of eosinophilic esophagitis.IL-13 is a therapeutic target in radiation lung injury.Pathway-based approaches to the treatment of inflammatory bowel disease.Pathogenic T cell subsets in allergic and chronic inflammatory bowel disorders.Tricellulin is regulated via interleukin-13-receptor α2, affects macromolecule uptake, and is decreased in ulcerative colitis.Targeted therapeutics for severe refractory asthma: monoclonal antibodies.Lessons Learned From Trials Targeting Cytokine Pathways in Patients With Inflammatory Bowel Diseases.Neutrophils in ulcerative colitis: a review of selected biomarkers and their potential therapeutic implications.Biomarkers in Search of Precision Medicine in IBD.Mucosal Expression of Type 2 and Type 17 Immune Response Genes Distinguishes Ulcerative Colitis From Colon-Only Crohn's Disease in Treatment-Naive Pediatric Patients.Immunological profiling of patients with ulcerative colitis leads to identification of two inflammatory conditions and CD1a as a disease marker Recent Advances: The Imbalance of Cytokines in the Pathogenesis of Inflammatory Bowel Disease.IL-33 Drives Eosinophil Infiltration and Pathogenic Type 2 Helper T-Cell Immune Responses Leading to Chronic Experimental Ileitis.Type 2 immunity in tissue repair and fibrosis.The Role of Cytokines in the Fibrotic Responses in Crohn's Disease.A mouse model for ulcerative colitis based on NOD-scid IL2R γnull mice reconstituted with peripheral blood mononuclear cells from affected individuals.A mechanistic PK/PD model for two anti-IL13 antibodies explains the difference in total IL-13 accumulation observed in clinical studies.Suppression of inflammation and tissue damage by a hookworm recombinant protein in experimental colitis.Usefulness of Transcriptional Blood Biomarkers as a Non-invasive Surrogate Marker of Mucosal Healing and Endoscopic Response in Ulcerative Colitis.Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis.Design and validation of a disease network of inflammatory processes in the NSG-UC mouse model.Old and New Lymphocyte Players in Inflammatory Bowel Disease.MicroRNA-31 and MicroRNA-155 Are Overexpressed in Ulcerative Colitis and Regulate IL-13 Signaling by Targeting Interleukin 13 Receptor α-1.Potential Risks Related to Modulating Interleukin-13 and Interleukin-4 Signalling: A Systematic Review.Effector T Helper Cell Subsets in Inflammatory Bowel Diseases.The Role of T-Cell Subsets in Chronic Inflammation in Celiac Disease and Inflammatory Bowel Disease Patients: More Common Mechanisms or More Differences?Mucosal-Associated Invariant T Cells in Autoimmune Diseases.New and Evolving Immunotherapy in Inflammatory Bowel Disease.Targeting IL-13 as a Host-Directed Therapy Against Ulcerative Colitis

P2860

Q26777429-252A83EC-DFD5-4E24-A63A-107835C69F1F Q26777729-1D313071-4846-4C7D-9A3C-6CF7AF250204 Q26797198-8A878BB6-512B-4561-8A11-6AB49EFD3E0E Q26799600-20AF9936-E4D0-4D2B-9087-88BCD5953012 Q28084792-BE6256EA-3B19-4955-9B5A-B8CA87AEBFFF Q35790968-02E811C1-F2C5-4139-BA9B-94FC1CAB6C83 Q36350271-366097FA-70BE-4315-B99E-F9BDABF1AD53 Q37012895-136DDA99-BB90-4C5A-B55F-78ABD10DEDB8 Q37526117-CCEC3292-343A-4D9C-8135-DF99B1E5951B Q38593257-AF79BF20-14FC-4233-8AFD-F5573ED989CF Q38665573-8EA54C14-2F10-44C7-87C4-4B80CDF42B8C Q38671207-E20E8891-D45B-41CC-A3BC-B34DBA25642A Q38790815-E9B35420-42D7-4370-A957-998D6AC9E2A0 Q38805575-CD29AD21-1BDF-45B8-9A67-960ECF2D47EB Q38950036-E2EC354A-B9CC-44E5-8316-BB524589537B Q38964878-061F611A-26D0-4907-B6B7-FB11AADA27ED Q38993044-C195BB07-FDA9-4794-8CBC-ED04CDDC0B29 Q39220077-86C85A95-BC5C-4EFB-9FDC-7E8DEF91FE71 Q39249504-C9FA48B3-F685-4A1A-B9CB-30A27822B0B3 Q39974669-E257A642-6CBD-428E-A331-F5934E8F8673 Q40074887-BFBADD4F-46FD-4BB9-B030-9E2D83B9711A Q41273741-D86A9EED-7538-4137-A7C7-232A44DA8B56 Q41285453-E88CB6F6-AF49-441B-9253-AE651811AD54 Q41873060-15B14406-AFD4-4C2E-B10A-3EF02EF55736 Q45740348-A9A1707F-6F50-41B3-98F0-A269AAA2C1FA Q47692659-CCC83899-AFA6-4EAD-BD93-B9DED15C7658 Q47958039-676BF3A0-5723-49FE-901C-96382FD4327B Q48340870-14D27490-1BBD-4AE5-B656-DF18B1880504 Q48351328-59908844-A001-4AEC-8130-6F415E237271 Q50042190-26468AEF-5C8A-42DA-AC85-6896DBA7779E Q50108035-48C81D74-C399-480D-BE88-E017B632C223 Q55176161-E03921EF-57CD-4E33-91DA-602B2C74F4B7 Q55222890-CCA457D3-83C9-4E26-BEA8-C02437862289 Q55301095-AB0423C5-72F0-4B32-AE8E-4F4E516B459F Q55379962-02EE5336-C887-4F87-98EC-69A084914764 Q59128301-9AD8420D-82A0-40D9-B45D-07AF9E4956A3

P2860

Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study.

http://www.wikidata.org/entity/Q44799322

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

Anrukinzumab, an anti-interleu ...... randomised multicentre study.

@en

Anrukinzumab, an anti-interleu ...... randomised multicentre study.

@nl

type

label

Anrukinzumab, an anti-interleu ...... randomised multicentre study.

@en

Anrukinzumab, an anti-interleu ...... randomised multicentre study.

@nl

prefLabel

Anrukinzumab, an anti-interleu ...... randomised multicentre study.

@en

Anrukinzumab, an anti-interleu ...... randomised multicentre study.

@nl

P1433

Q44799322-8B52151D-E19A-41DF-9E8D-38BA1261F674

P1476

Q44799322-D50460A7-73BE-4E6C-B819-3123BCE4356A

P2093

Q44799322-28A1CD71-E249-4C13-9E5B-1AC5E628580C

Q44799322-3B9E0C99-C39B-4656-9E05-5EEF3A93BF30

Q44799322-465E2B14-26D3-4C32-A1A4-981C260C30D7

Q44799322-48CF7A9A-85D3-4812-B213-4B4FC8ED4ACF

Q44799322-55AA71B5-923E-4A43-85FF-42CE211DD966

Q44799322-5CB64A03-F598-4ADC-8055-78CFD77850FF

Q44799322-7E2AB8AF-FB2A-440C-9D6D-7CF346A77659

Q44799322-A033D254-AC4F-4EA3-8101-4032727E4C56

Q44799322-B825267D-2822-4BD3-BAB6-ED7FC4E8D373

Q44799322-C7D8E381-DE06-4F33-8C95-39CB2D1424D9

P2860

Q44799322-0C66EA6B-667D-4BF8-B127-4FA26D4AE29D

Q44799322-19362812-DDB8-49B2-A324-F59CC3565FB2

Q44799322-53453B48-2177-4583-B9F7-9AB8E475023F

Q44799322-748226B7-E1E8-4752-B880-0FB60A2D154E

Q44799322-7BBB958D-7E71-47FB-A702-27B6D491191A

Q44799322-B305202D-F333-41C6-AD62-D206389394E3

Q44799322-D715B8CC-6B8A-4AB8-839F-C03AE3F16CD5

Q44799322-E9385DBF-4328-4461-8CFF-BA39E1E1A4F0

Q44799322-FE592038-4006-412E-9A8F-A14E68CB50C6

P304

Q44799322-074E69C2-E2A2-455C-86AE-27FB014E2839

P31

Q44799322-9322FB62-E41E-499C-B5AC-BC971EF0900D

P356

Q44799322-DE664CB6-C9C8-4DD3-959E-00EAF0EBF82D

P407

Q44799322-BF32EB41-5F5D-4EED-8C74-4E32D221349B

P433

Q44799322-C9A71E74-785F-4C18-8C14-0FA864826432

P478

Q44799322-7033424F-0153-4CC9-9FFF-E3E366A0A902

P50

Q44799322-411D031B-3676-460C-A184-0C743355F30C

P577

Q44799322-E8102D2D-D49D-4D6E-BF85-F8DCBB3D5719

P698

Q44799322-11BB3153-8070-4B65-80BC-BA26D5AFCB1A

P921

Q44799322-110776AA-1EA9-4293-A486-5CE617A8670A

Q44799322-b7428302-a862-4aae-9c30-4a15e2ef073b

P356

GUTJNL-2014-308337

P1433

P1476

Anrukinzumab, an anti-interleu ...... randomised multicentre study.

@en

P2093

Fabio Cataldi

http://www.w3.org/2001/XMLSchema#string

Fei Hua

http://www.w3.org/2001/XMLSchema#string

Gabor Toth

http://www.w3.org/2001/XMLSchema#string

Gail M Comer

http://www.w3.org/2001/XMLSchema#string

Hua Zhu

http://www.w3.org/2001/XMLSchema#string

Karen Page

http://www.w3.org/2001/XMLSchema#string

Margot O'Toole

http://www.w3.org/2001/XMLSchema#string

Michelle Hinz

http://www.w3.org/2001/XMLSchema#string

Sunil Khurana

http://www.w3.org/2001/XMLSchema#string

Tara McDonnell Moorehead

http://www.w3.org/2001/XMLSchema#string

P2860

Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis.

IL-13 receptors and signaling pathways: an evolving web.

Elevated IL-13Ralpha2 in intestinal epithelial cells from ulcerative colitis or colorectal cancer initiates MAPK pathway

Interleukin 13 and its role in gut defence and inflammation.

Upregulation of IL-13 concentration in vivo by the IL13 variant associated with bronchial asthma.

Interleukin-13 neutralization by two distinct receptor blocking mechanisms reduces immunoglobulin E responses and lung inflammation in cynomolgus monkeys.

The primary binding subunit of the human interleukin-4 receptor is also a component of the interleukin-13 receptor.

IL-13 blockade reduces lung inflammation after Ascaris suum challenge in cynomolgus monkeys.

Efficacy of IL-13 neutralization in a sheep model of experimental asthma.

P304

894-900

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/GUTJNL-2014-308337

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

64

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-01-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25567115

http://www.w3.org/2001/XMLSchema#string

P921